(71 days)
Not Found
No
The document describes a bone graft material and its intended uses, with no mention of AI or ML technology in its description, intended use, or performance studies.
No.
The device is a bone filling and augmentation material, not a therapeutic device designed to cure, treat, prevent, or diagnose disease. Its function is to augment bony defects.
No
The device is described as a bone filling and augmentation material used in dental applications, not for diagnosing conditions.
No
The device description clearly states that C-GRAFT™ is a physical bone filling and augmentation material provided in pre-filled vials, indicating it is a hardware device, not software.
Based on the provided information, C-GRAFT™ is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use of C-GRAFT™ is for bone filling and augmentation in dental applications. This involves physically interacting with and modifying the body (specifically bone tissue), not analyzing samples taken from the body to diagnose a condition.
- Device Description: The description details a material used for grafting, not a reagent, instrument, or system intended for in vitro examination of specimens.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), detecting markers, or providing diagnostic information.
IVDs are devices used to examine specimens derived from the human body in vitro (outside the body) to provide information for diagnostic, monitoring, or compatibility purposes. C-GRAFT™ does not fit this definition.
N/A
Intended Use / Indications for Use
C-GRAFT™ is indicated for:
- Treatment of intrabony defects; .
- Augmentation of bony defects of alveolar ridge; .
- Filling of extraction sites; and .
- Sinus elevation grafting. .
Product codes (comma separated list FDA assigned to the subject device)
LYC
Device Description
C-GRAFT™ is a bone filling and augmentation matcrial indicated for use in dental applications. C-GRAFT™ is an inorganic, biocompatible calcium phosphate material derived from calcium-encrusted red sea algae. The algae are processed in order to develop an apatite material that is analogous to bone apatite. C-GRAFT™ is provided sterile in pre-filled vials and has a granule size range from 300-1000 microns.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance evaluations of C-GRAFT™ testing reports when compared to those of FRIOS® ALGIPORE® show that the two materials are equivalent both chemically and mineralogically. Comparisons of C-GRAFT™ to the predicate devices show the device to be substantially cquivalent.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 872.3930 Bone grafting material.
(a)
Identification. Bone grafting material is a material such as hydroxyapatite, tricalcium phosphate, polylactic and polyglycolic acids, or collagen, that is intended to fill, augment, or reconstruct periodontal or bony defects of the oral and maxillofacial region.(b)
Classification. (1) Class II (special controls) for bone grafting materials that do not contain a drug that is a therapeutic biologic. The special control is FDA's “Class II Special Controls Guidance Document: Dental Bone Grafting Material Devices.” (See § 872.1(e) for the availability of this guidance document.)(2) Class III (premarket approval) for bone grafting materials that contain a drug that is a therapeutic biologic. Bone grafting materials that contain a drug that is a therapeutic biologic, such as biological response modifiers, require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
0
KO33110
DEC 1 0 2003
SECTION 14: SUMMARY OF SAFETY AND EFFECTIVENESS
This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and CFR 807.92.
SUBMITTER INFORMATION 14.1
- The Clinician's Preference LLC a. Company Name: 25188 Gennesse Trail Rd, Suite 150 b. Company Address: Golden, CO 80401 (303) 526-1041 Company Phone: ﻥ (303) 526-0695 Company Facsimile: Michael Czuchna d. Contact Person: Manager, RA and QA/QC
- September 27, 2003 e. Date Summary Prepared:
DEVICE IDENTIFICATION 14.2
| a. | Trade/Proprietary Name: | C-GRAFTTM |
|---|---|---|
| b. | Classification Name: | Bone filling and augmentation |
| material unclassified | ||
| c. | Product Code: | LYC |
ﺮ ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ، ،
IDENTIFICATION OF PRECATE DEVICES 14.3 510(k) No. Date Cleared Device Company 03/28/1995 Interpore® 200 Granular K950165 Interpore Coralline Hydroxylapatite International OsteoGraf® / N-700 06/26/1998 K981214 CeraMed Dental K023799 02/05/2003 FRIOS® ALGIPORE® Friadent GMBH
1
DEVICE DESCRIPTION 14.4
C-GRAFT™ is a bone filling and augmentation matcrial indicated for use in dental applications. C-GRAFT™ is an inorganic, biocompatible calcium phosphate material derived from calcium-encrusted red sea algae. The algae are processed in order to develop an apatite material that is analogous to bone apatite. C-GRAFT™ is provided sterile in pre-filled vials and has a granule size range from 300-1000 microns.
14.5 SUBSTANTIAL EQUIVALENCE
C-GRAFT™ is substantially equivalent to Friadent GMBH FRIOS® ALGIPORE® in terms of material composition, chemical analysis, functionality and intended use. C-GRAFT™ is also substantially cquivalent to Interporc International Interpore® 200 Granular Coralline Hydroxylapatite and CcraMed Dental OsteoGraf® / N-700 in terms of material, functionality, and intended use.
INTENDED USE 14.6
C-GRAFT™ is indicated for:
- Treatment of intrabony defects; .
- Augmentation of bony defects of alveolar ridge; .
- Filling of extraction sites; and .
- Sinus elevation grafting. .
TECHNOLOGICAL CHARACTERISTICS 14.7
C-GRAFT™ is equivalent to FRIOS® ALGIPORE® in terms of chemical composition. Tests were completed on the two materials to determine the chcmical and mineralogical compositions using Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and X-ray Diffraction. Results of the tests show that the materials are equivalent in composition and meet the ASTM standard
2
specifications for the composition of hydroxylapatite for surgical implants (ASTM F 1185-88).
14.8 CONCLUSIONS
This notification contains all information required by 21 CFR 807.87. A completed copy of the Premarket Notification 510(k) Review's Checklist is provided with this submission. Performance evaluations of C-GRAFT™ testing reports when compared to those of FRIOS® ALGIPORE® show that the two materials are equivalent both chemically and mineralogically. Comparisons of C-GRAFT™ to the predicate devices show the device to be substantially cquivalent.
3
Image /page/3/Picture/1 description: The image shows the seal of the Department of Health & Human Services - USA. The seal is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is an emblem of a stylized eagle with its wings spread, with three wavy lines below it.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
DEC 1 0 2003
The Clinician's Preference LLC Mr. Charles L. Morin Regulatory counsel Morin & Associates 388 Market Street, Suite 500 San Francisco, California 94111
Re: K033110
Trade/Device Name: C-GRAFTTM Regulation Number: Unclassified Regulation Name: None Regulatory Class: None Product Code: LYC Dated: September 27, 2003 Received: September 30, 2003
Dear Mr. Morin:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition. FDA may publish further announcements concerning your device in the Federal Register.
4
Page 2 - Mr. Morin
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4613. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
Clus
Chiu Lin. Ph.D. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
INDICATION FOR USE
510(k) Number:
Device Name:
C-GRAFT™
长033110
Indications for Use:
C-GRAFT™ is indicated for:
- Augmentation of bony defects of the alveolar ridge 트
- 미 Sinus elevation grafting
- Treatment of intrabony periodontal defects 도
- 트 Extraction socket grafting
(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEED)
Concurrence of CDRH, office of Device Evaluation (ODE)
| Prescription Use | / | OR | Over-The-Counter Use |
|---|---|---|---|
| (Per 21 CFR 801.109) |
(Division Sign-Off)
Division of Anesthesiology, General Hospital,
Infection Control, Dental Devices
| 510(k) Number | K033110 |
|---|---|
| --------------- | --------- |